Q-omics provides the consensus-scored BIRC3 profile across patient tissues and cancer cell-line models. BIRC3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, BIRC3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, BIRC3 RNA expression shows 21,355 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where BIRC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BIRC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BIRC3 survival associations across molecular data types. BIRC3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BIRC3 RNA expression–survival associations across cancer types. High BIRC3 expression shows unfavorable associations in KIRP, UVM and LGG, but favorable associations in SKCM, HNSC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for BIRC3 RNA expression.
This table summarizes BIRC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BIRC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BIRC3 shows lower tumor expression in BLCA, KICH, LUSC and COAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher BIRC3 RNA expression in tumor versus normal tissue (log2 FC = +2.719, t-test p < 0.001).
This table shows molecular features associated with BIRC3 in patient tissues and cancer cell lines. In patient samples, BIRC3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BIRC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
